Songhori N, Goushky M, Khaleghi M, Mojerloo M, Sadeghi M, Mozafar M
Health Sci Rep. 2025; 8(3):e70534.
PMID: 40078900
PMC: 11896815.
DOI: 10.1002/hsr2.70534.
Mravinacova S, Bergstrom S, Olofsson J, de San Jose N, Anderl-Straub S, Diehl-Schmid J
Sci Rep. 2025; 15(1):668.
PMID: 39753643
PMC: 11698900.
DOI: 10.1038/s41598-024-83281-y.
Sadeghi M, Azargoonjahromi A, Nasiri H, Yaghoobi A, Sadeghi M, Chavoshi S
Mol Brain. 2024; 17(1):60.
PMID: 39215335
PMC: 11363600.
DOI: 10.1186/s13041-024-01136-z.
Bartl M, Nilsson J, Dakna M, Weber S, Schade S, Xylaki M
NPJ Parkinsons Dis. 2024; 10(1):102.
PMID: 38760408
PMC: 11101466.
DOI: 10.1038/s41531-024-00714-1.
Hong C, Chung C, Yu R, Chan L
Elife. 2024; 12.
PMID: 38483306
PMC: 10939498.
DOI: 10.7554/eLife.87501.
CSF protein ratios with enhanced potential to reflect Alzheimer's disease pathology and neurodegeneration.
Mravinacova S, Alanko V, Bergstrom S, Bridel C, Pijnenburg Y, Hagman G
Mol Neurodegener. 2024; 19(1):15.
PMID: 38350954
PMC: 10863228.
DOI: 10.1186/s13024-024-00705-z.
CSF GAP-43 as a biomarker of synaptic dysfunction is associated with tau pathology in Alzheimer's disease.
Qiang Q, Skudder-Hill L, Toyota T, Wei W, Adachi H
Sci Rep. 2022; 12(1):17392.
PMID: 36253408
PMC: 9576773.
DOI: 10.1038/s41598-022-20324-2.
Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals.
Ohrfelt A, Benedet A, Ashton N, Kvartsberg H, Vandijck M, Weiner M
Neurology. 2022; 100(3):e275-e285.
PMID: 36192174
PMC: 9869758.
DOI: 10.1212/WNL.0000000000201417.
Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment.
Lu Y
Aging Clin Exp Res. 2022; 34(10):2399-2406.
PMID: 35988117
DOI: 10.1007/s40520-022-02202-z.
CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study.
Mila-Aloma M, Brinkmalm A, Ashton N, Kvartsberg H, Shekari M, Operto G
Neurology. 2021; 97(21):e2065-e2078.
PMID: 34556565
PMC: 8610620.
DOI: 10.1212/WNL.0000000000012853.
Neuromodulatory effects of repetitive transcranial magnetic stimulation on neural plasticity and motor functions in rats with an incomplete spinal cord injury: A preliminary study.
Marufa S, Hsieh T, Liou J, Chen H, Peng C
PLoS One. 2021; 16(6):e0252965.
PMID: 34086836
PMC: 8177618.
DOI: 10.1371/journal.pone.0252965.
Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.
McGrowder D, Miller F, Vaz K, Nwokocha C, Wilson-Clarke C, Anderson-Cross M
Brain Sci. 2021; 11(2).
PMID: 33578866
PMC: 7916561.
DOI: 10.3390/brainsci11020215.
Biomarkers: Our Path Towards a Cure for Alzheimer Disease.
Tarawneh R
Biomark Insights. 2020; 15:1177271920976367.
PMID: 33293784
PMC: 7705771.
DOI: 10.1177/1177271920976367.
Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?.
Bloniecki V, Zetterberg H, Aarsland D, Vannini P, Kvartsberg H, Winblad B
Alzheimers Res Ther. 2020; 12(1):153.
PMID: 33203439
PMC: 7670701.
DOI: 10.1186/s13195-020-00718-y.
Fluid Biomarkers for Synaptic Dysfunction and Loss.
Camporesi E, Nilsson J, Brinkmalm A, Becker B, Ashton N, Blennow K
Biomark Insights. 2020; 15:1177271920950319.
PMID: 32913390
PMC: 7444114.
DOI: 10.1177/1177271920950319.
Blood neuro-exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage.
Jia L, Zhu M, Kong C, Pang Y, Zhang H, Qiu Q
Alzheimers Dement. 2020; 17(1):49-60.
PMID: 32776690
PMC: 7984076.
DOI: 10.1002/alz.12166.
From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy.
Colin M, Dujardin S, Schraen-Maschke S, Meno-Tetang G, Duyckaerts C, Courade J
Acta Neuropathol. 2019; 139(1):3-25.
PMID: 31686182
PMC: 6942016.
DOI: 10.1007/s00401-019-02087-9.
Expression and secretion of synaptic proteins during stem cell differentiation to cortical neurons.
Nazir F, Becker B, Brinkmalm A, Hoglund K, Sandelius A, Bergstrom P
Neurochem Int. 2018; 121:38-49.
PMID: 30342961
PMC: 6232556.
DOI: 10.1016/j.neuint.2018.10.014.
Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology.
Sandelius A, Portelius E, Kallen A, Zetterberg H, Rot U, Olsson B
Alzheimers Dement. 2018; 15(1):55-64.
PMID: 30321501
PMC: 6333489.
DOI: 10.1016/j.jalz.2018.08.006.
Cerebrospinal fluid GAP-43 in early multiple sclerosis.
Rot U, Sandelius A, Emersic A, Zetterberg H, Blennow K
Mult Scler J Exp Transl Clin. 2018; 4(3):2055217318792931.
PMID: 30094057
PMC: 6081760.
DOI: 10.1177/2055217318792931.